**Table 3.** Association between positivity of any of the serum autoimmune antibodies or ANA positivity and presence of advanced liver fibrosis in patients with biopsy-proven NAFLD

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Variable | Model 1 |  | Model 2 |  | Model 3 |  | Model 4 |  |
|  | OR (95% CI) | *P* | OR (95% CI) | *P* | OR (95% CI) | *P* | OR (95% CI) | *P* |
| Age (years) | 1.01 (0.97-1.05) | 0.60 | 1.02 (0.98-1.06) | 0.48 | *not included* | - | *not included* | - |
| Sex (male) | 0.50 (0.18-1.38) | 0.19 | 0.53 (0.19-1.46) | 0.22 | *not included* | - | *not included* | - |
| Women > 50 years old | *not included* | - | *not included* | - | 8.39 (2.82-24.9) | < 0.001 | 8.04 (2.69-24.1) | < 0.001 |
| ANA positivity (yes vs. no) | 4.51 (1.77-11.5) | 0.002 | *not included* | - | 6.42 (2.39-17.2) | < 0.001 | *not included* | - |
| Autoimmune antibody positivity | *not included* | - | 3.14 (1.30-7.62) | 0.01 | *not included* | - | 4.15 (1.65-10.4) | 0.002 |
| Waist circumference (cm) | 1.01 (0.95-1.06) | 0.84 | 1.00 (0.95-1.06) | 0.90 | 1.01 (0.96-1.07) | 0.75 | 1.01 (0.95-1.06) | 0.86 |
| Type 2 diabetes (yes vs. no) | 2.72 (1.07-6.92) | 0.04 | 2.65 (1.04-6.75) | 0.04 | 2.61 (0.99-6.79) | 0.05 | 2.52 (0.96-6.59) | 0.06 |
| Hypertension (yes vs. no) | 0.94 (0.31-2.81) | 0.91 | 0.92 (0.30-2.78) | 0.88 | 0.61(0.19-1.94) | 0.40 | 0.58 (0.18-1.91) | 0.37 |
| Total NAS | 1.09 (0.78-1.50) | 0.62 | 1.07 (0.78-1.48) | 0.67 | 1.03 (0.75-1.42) | 0.86 | 1.00 (0.73-1.38) | 0.98 |
| Serum ALT (IU/L) | 0.92 (0.52-1.63) | 0.77 | 0.95 (0.55-1.64) | 0.84 | 0.98 (0.67-1.44) | 0.93 | 1.00 (0.67-1.50) | 0.99 |

Cohort size, n=388. Multivariable logistic regression analysis was used to examine either the association between ANA positivity and advanced fibrosis (i.e., histologic F3-F4 stages) in adjusted models 1 and 3, or the association between any autoimmune antibody positivity and advanced fibrosis in adjusted models 2 and 4. Regression models 1 and 2 were adjusted for age, sex, waist circumference, type 2 diabetes, hypertension, total NAS and ALT; models 3 and 4 were adjusted for women > 50 years old, waist circumference, type 2 diabetes, hypertension, total NAS and ALT. In all these regression models the presence of advanced fibrosis (F3-F4) was included as the dependent variable.

*Abbreviations*: OR: odds ratio; CI: confidence interval; NAS: NAFLD activity score; ALT: alanine aminotransferase.